One-shot Johnson & Johnson COVID-19 vaccine is less effective against the Delta variant
The Johnson & Johnson COVID-19 vaccine is less effective against the Indian ‘Delta’ coronavirus variant than other shots, a new study suggests.
Researchers found that antibody levels from people who received the one-dose vaccine were twice as low compared to those given the two-dose Pfizer-BioNTech or Moderna vaccines.
The findings add to the growing body of evidence that the 13 million Americans who received J&J will need boosters to protect against highly infectious variants.
It comes as Dr Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), testified before the Senate Health, Education, Labor and Pensions committee on Wednesday that the variant makes up 83 percent of all new cases.
Antibody levels among people who received Johnson & Johnson’s COVID-19 vaccine were low against the Indian ‘Delta’ coronavirus variant. Pictured: Johnson & Johnson’s Covid-19 vaccines are seen on a table in Los Angeles, mAY 2021
In the study, which has not been peer-reviewed, blood samples from patients vaccinated the three approved shots were tested against the variant.
Researchers found that antibody levels in J&J patients were five to seven times lower when exposed to the Delta variant.
Comparatively, levels in Pfizer and Moderna patients were three-fold lower.
The findings are in line with a UK study, which found that the AstraZeneca vaccine – which is made with the same technology that the J&J vaccine uses – is 33 percent effective against symptomatic disease caused by Delta.
‘The message that we wanted to give was not that people shouldn’t get the J.&J. vaccine, but we hope that in the future, it will be boosted with either another dose of J&J or a boost with Pfizer or Moderna,’ lead author Dr Nathaniel Landau, a virologist at NYU’s Grossman School of Medicine, told The New York Times.
This is a breaking news story and will be updated.